Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | BCL9 | O00512 | 1/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749001 | 0.93 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19CHRM4 | |
| SCHEMBL25329767 | 0.91 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19CHRM4 | |
| SCHEMBL4462505 | 0.91 | GRIN2B (0.66) | SMN1; SMN2NPC1RAB9ACYP2C19CHRM4 | |
| SCHEMBL15747803 | 0.91 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19CHRM4 | |
| SCHEMBL7503285 | 0.90 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19CHRM4 | |
| SCHEMBL2384566 | 0.90 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19CHRM4 | |
| SCHEMBL6745783 | 0.90 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19CHRM4 | |
| SCHEMBL8316392 | 0.88 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19CHRM4 | |
| SCHEMBL6749790 | 0.88 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19CHRM4 | |
| SCHEMBL6747336 | 0.88 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119677723-A | Difluoro and trifluoroacetyl hydrazides as selective HDAC6 inhibitors | 意大发马克股份公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4543895-A1 | NOVEL IRON-BASED COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF AS CATALYSTS | Université Paris-Saclay (FR) | 2025-04-30 | — | — | EP | disclosed |
| CN-119677723-A | Difluoro and trifluoroacetyl hydrazides as selective HDAC6 inhibitors | 意大发马克股份公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12076715-B1 | Synthesis and characterization of air-stable iron-based catalysts for Suzuki-Miyaura cross-coupling reactions of alkyl halides and aryl boronic esters | THE TRUSTEES OF BOSTON COLLEGE (MA) | 2024-09-03 | — | — | US | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| EP-1501467-A4 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1501467-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003088908-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12076715-B1 | Synthesis and characterization of air-stable iron-based catalysts for Suzuki-Miyaura cross-coupling reactions of alkyl halides and aryl boronic esters | NBAS, BLVRB, TFRC | SMN1; SMN2 1821/4885NPC1 1611/4885RAB9A 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.